AB
Therapeutic Areas
GRAIL Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Galleri® Test | Multi-Cancer Early Detection (MCED) | Approved/Commercial |
| REACH/Galleri-Medicare Study | Real-world clinical impact of Galleri | Observational Study |
| PATHFINDER 2 Study | Clinical implementation of Galleri | Interventional Study |
| NHS-Galleri Trial | Population screening utility of Galleri | Phase 3 |
| SUMMIT Study | MCED in lower-risk population | Observational Study |
| STRIVE Study | Refining Galleri prediction in women | Observational Study |
| CCGA Study | Foundational assay development for MCED | Observational Study |
| PATHFINDER Study | Early clinical implementation of MCED | Interventional Study |
Leadership Team at GRAIL
BR
Bob Ragusa
Chief Executive Officer and Board Member
JO
Joshua Ofman
President
AF
Aaron Freidin
Chief Financial Officer
SH
Sir Harpal Kumar
Chief Scientific Officer & President International
AP
Andy Partridge
Chief Commercial Officer
SA
Satnam Alag
Senior Vice President, Software Engineering and Chief Security Officer
PC
Paul Ciccolella
Senior Vice President, Global Development & Operations
EF
Eric Fung
SVP, Clinical Development
AH
Alison Highlander
Senior Vice President, Human Resources; Head of People Team
LP
Linda Peters
SVP, Quality & Regulatory